Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The EORTC 22922/10925 trial investigating regional nodal irradiation in stage I-III breast cancer: Outcomes according to locoregional and systemic therapies.
Kaidar-Person O, Boersma LJ, De Brouwer P, Weltens C, Kirkove C, Peignaux-Casasnovas K, Budach V, van der Leij F, Peters M, Weidner N, Rivera S, van Tienhoven G, Fourquet A, Noel G, Valli M, Guckenberger M, Koiter E, Racadot S, Abdah-Bortnyak R, Bartelink H, Struikmans H, Fortpied C, Poortmans PM; EORTC Radiation Oncology and Breast Cancer Groups. Kaidar-Person O, et al. Among authors: poortmans pm. Radiother Oncol. 2024 Dec;201:110563. doi: 10.1016/j.radonc.2024.110563. Epub 2024 Sep 26. Radiother Oncol. 2024. PMID: 39341505 Clinical Trial.
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Bartelink E, Borger JH, Brenninkmeyer SJ, Horiot JC, Pierart M, Poortmans PM, Struikmans H, Van der Schueren E, Van Dongen JA, Van Limbergen E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):667-76. doi: 10.1016/s0360-3016(99)00215-1. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524421 Clinical Trial.
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Van der Hulst M, Van der Schueren E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85. doi: 10.1016/s0360-3016(99)00211-4. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524422 Clinical Trial.
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, Pierart M, Poortmans PM, Struikmans H, Maat B, Van Limbergen E, Bartelink H. Vrieling C, et al. Among authors: poortmans pm. Radiother Oncol. 2000 Jun;55(3):219-32. doi: 10.1016/s0167-8140(00)00210-3. Radiother Oncol. 2000. PMID: 10869738 Clinical Trial.
The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomized trial 22922/10925 in Stage I--III breast cancer(1).
Poortmans PM, Venselaar JL, Struikmans H, Hurkmans CW, Davis JB, Huyskens D, van Tienhoven G, Vlaun V, Lagendijk JJ, Mijnheer BJ, De Winter KA, Van der Hulst MH, Van den Bogaert WF. Poortmans PM, et al. Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1399-408. doi: 10.1016/s0360-3016(00)01549-2. Int J Radiat Oncol Biol Phys. 2001. PMID: 11286848 Clinical Trial.
Quality assurance in the EORTC 22921 trial on preoperative radiotherapy with or without chemotherapy for resectable rectal cancer: evaluation of the individual case review procedure.
Kouloulias VE, Bosset JF, van Tienhoven G, Davis BJ, Pierart M, Poortmans P; EORTC Radiotherapy Group. European Organization for Research and Treatment of Cancer. Kouloulias VE, et al. Eur J Cancer. 2002 Sep;38(14):1849-56. doi: 10.1016/s0959-8049(02)00174-0. Eur J Cancer. 2002. PMID: 12204666 Clinical Trial.
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Van den Bogaert W, Bartelink H; EORTC Radiotherapy, Breast Cancer Groups. Vrieling C, et al. Among authors: poortmans pm. Eur J Cancer. 2003 May;39(7):932-44. doi: 10.1016/s0959-8049(03)00123-0. Eur J Cancer. 2003. PMID: 12706362 Clinical Trial.
The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial.
Poortmans P, Bartelink H, Horiot JC, Struikmans H, Van den Bogaert W, Fourquet A, Jager J, Hoogenraad W, Rodrigus P, Wárlám-Rodenhuis C, Collette L, Pierart M; EORTC Radiotherapy and Breast Cancer Groups. Poortmans P, et al. Radiother Oncol. 2004 Jul;72(1):25-33. doi: 10.1016/j.radonc.2004.03.007. Radiother Oncol. 2004. PMID: 15236871 Clinical Trial.
325 results